Staged IOL implantation = happy patients

Article

By employing staged implantation of intraocular lenses (IOLs), surgeons can produce the best possible visual outcomes for each individual patient.

By employing staged implantation of intraocular lenses (IOLs), surgeons can produce the best possible visual outcomes for each individual patient, according to Richard Lindstrom from Minnesota, USA.

Dr Lindstrom conducted a case series in which 23 patients received a dual diffractive IOL combination (ReStor/ReStor; Alcon) and 29 patients were implanted with a diffractive/refractive IOL combination (ReStor/ReZoom; AMO), using the process of staged implantation.

It was discovered that patient satisfaction with distance vision improved from 74% with the dual diffractive IOLs to 96% with the diffractive/refractive combination. Satisfaction with near vision improved from 83% to 96% and willingness to recommend the procedure to others improved from 64% to 96%. Furthermore, subjects with the diffractive/refractive combination reported spectacle independence 94% of the time, compared with just 65% of the time for the subjects with the dual diffractive IOLs.

Dr Lindstrom believes that the staged process can provide the best possible visual outcomes and that combining two different types of refractive IOLs leads to high levels of spectacle independence and patient satisfaction.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.